The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

UAMS Winthrop P. Rockefeller Cancer Institute joins Kiyatec clinical study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences has joined the 3D-PREDICT clinical study, by Kiyatec Inc., to validate the company’s test as a patient-specific predictor of response to recommended drug therapies for patients with ovarian cancer.

“We developed our investigational ovarian cancer drug response profile to help optimize therapeutic decision-making over the course of the disease,” Matthew Gevaert, CEO of Kiyatec, said in a statement.

3D-PREDICT is a prospective, open-label, non-interventional study to validate Kiyatec’s ovarian cancer drug response profile, which leverages the company’s ex vivo 3D cell culture technology platform to assess pre-treatment, patient-specific response to a panel of 11 drugs most commonly used to treat patients with newly diagnosed or recurrent ovarian cancer.

Kiyatec uses its ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors.

Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
By Sara Willa Ernst and Paul Goldberg
Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account